Barclays
IBRX icon

Barclays’s ImmunityBio IBRX Stock Holding History

Barclays’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-189,600
Closed -$1.45M – 5479
2026
Q1 		$1.45M Buy
+189,600
New +$1.3M ﹤0.01% 2534
2025
Q3 		– Sell
-120,000
Closed -$317K – 5599
2025
Q2 		$317K Buy
+120,000
New +$323K ﹤0.01% 4021
2024
Q2 		– Sell
-197,300
Closed -$1.06M – 5067
2024
Q1 		$1.06M Buy
+197,300
New +$893K ﹤0.01% 3074

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's IBRX Position: Q2 2026 in Review

Barclays reduced its ImmunityBio (IBRX) stake by 61% in Q2 2026, selling an estimated $8.78M and leaving 730,336 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1718.

Barclays first reported a position in IBRX in Q4 2015 and has held it in 39 quarters since. The position peaked at $14.5M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Barclays held 730,336 shares of ImmunityBio worth $6.39M as of Q2 2026.
  • Barclays sold 1,159,764 ImmunityBio shares in Q2 2026, an estimated $8.78M.
  • ImmunityBio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1718 holding.
  • Barclays first reported a position in ImmunityBio in Q4 2015 and has held it in 39 quarters since.
  • Barclays's ImmunityBio position peaked at $14.5M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.